TICKERNERD
Menu
PETSPETSHealthcare · Pharmaceutical Retailers

PETS Stock Forecast: PetMed Express, Inc. Price Predictions for 2026-2027

Last close, 12 Oct 2026
$1.26
−2.33% on the day

The 1 Wall Street analysts covering PetMed Express, Inc. hold a median 12-month price target of $1.4 — +11.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 12 Oct 2026 — in the lower half.

Market cap
$28.0M
Ticker Nerd rank
47 / 100
Median analyst target
$1.40
Analysts covering
1
Revenue$41.0M−19.9% y/y
Operating income−$6.2M
Net income−$6.1M
Free cash flow−$8.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.5%
1M
−23.6%
YTD
−60.6%
1Y
−47.9%
From 52W high
−67.7%
From 52W low
0.0%
$1.26
$3.90
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PETS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores PetMed Express, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Oct 2026
47 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
86
Accruals
77
Issuance
68
Quality
46
Volatility
44
Momentum
44
Value
38
Revisions
32
Growth
30

Size (86): Smaller than most of the companies we track.

Growth (30): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PETS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PETS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$1.50$2.00$2.50$3.00$3.50$4.00$4.50Jan 26Apr 26Jul 26Oct 26PETSHigh $1.40Median $1.40Low $1.40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0 Buy0 Hold1 Sell
Low $1.40Median $1.40High $1.40

The green dot is the last close — the median target sits +11.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
25 Sept 2026Morgan StanleyMaintainsUnderweight$2.15 → $1.40
17 Apr 2025Morgan StanleyMaintainsUnderweight$3.50 → $3.20
17 Apr 2025Morgan StanleyMaintainsUnderweight—
7 Aug 2024Lake StreetDowngradeHold—
12 June 2024Lake StreetMaintainsBuy—
12 June 2024Morgan StanleyMaintainsUnderweight—
16 Nov 2023Morgan StanleyMaintainsUnderweight—
31 Oct 2023Morgan StanleyMaintainsUnderweight—
19 Oct 2023Morgan StanleyMaintainsUnderweight—
27 July 2023Morgan StanleyReiteratesUnderweight—
25 May 2023Lake StreetInitiatesBuy—
23 Mar 2023Morgan StanleyMaintainsUnderweight—
8 Nov 2022Morgan StanleyMaintainsUnderweight—
26 July 2022Morgan StanleyMaintainsUnderweight—
10 May 2022Morgan StanleyMaintainsUnderweight—
25 Jan 2022Morgan StanleyMaintainsUnderweight—
20 Jan 2022Sidoti & Co.UpgradeBuy—
18 Nov 2021Morgan StanleyInitiatesUnderweight—
1 Oct 2021JefferiesInitiatesHold—
3 June 2021Sidoti & Co.DowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PETS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PETS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 12 Oct 2026, PetMed Express, Inc. returned −47.9% against +20.4% for the S&P 500, dividends included.

PETS vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160Jan 26Apr 26Jul 26Oct 26PETSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PETS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−814.3%
Analysts raising
0
Analysts cutting
1
Fundamentals

PetMed Express, Inc. (PETS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
257.0×

Cheaper than 3% of US stocks

Price / sales
0.2×

Cheaper than 93% of US stocks

Price / book
1.2×

Cheaper than 65% of US stocks

EV / EBITDA
−0.8×

Cheaper than 67% of US stocks

Growth & margins
Revenue growth (YoY)
−19.9%

Higher than 11% of US stocks

Earnings growth (YoY)
−19.9%

Higher than 21% of US stocks

Gross margin
27.6%

Higher than 31% of US stocks

Operating margin
−15.2%

Higher than 23% of US stocks

Net margin
−17.3%

Higher than 16% of US stocks

Returns & dividend
Return on equity
−78.6%

Higher than 16% of US stocks

Return on assets
−20.0%

Higher than 19% of US stocks

Dividend yield
93.8%

Higher than 99% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

PetMed Express, Inc. (PETS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • PetMed Express, Inc. has a market value of $28.0M and an enterprise value of $14.3M.

  • Revenue in the twelve months to 30 June 2026: $168.9M. The latest quarter shrank 19.9% year on year.

  • Net income over the same four quarters: −$29.3M, a −17.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.38.

  • Free cash flow in the twelve months to 30 June 2026: −$27.8M.

  • PetMed Express, Inc. spent $20K on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 21.7M.

  • Trailing P/E: 257.0×; forward P/E: −42.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 93.75%, paying out 0% of earnings.

  • PetMed Express, Inc. employs 189 people — $893K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

PETS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelPharmaceutical Retailers
CompanyMarket capTKN rank
PETSPetMed Express, Inc.$28.0M
47
SCNXScienture Holdings, Inc.$6.4M
7
HITIHigh Tide, Inc.$233.2M
—
PMIPicard Medical, Inc.*$26.5M
26
RNAZTransCode Therapeutics, Inc.*$27.6M
22
ITOCiTonic Holdings Ltd.*$26.2M
19
ABVCABVC BioPharma, Inc.*$26.1M
11

* Nearest Healthcare names by size — few pharmaceutical retailers companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own PetMed Express, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PETS news & analysis

PetMeds Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 2 Oct 2026neutral

PetMed Express, Inc. (PetMeds) announced that it granted equity awards previously approved by its Board of Directors to two newly hired executives as a material inducement to employment, under Nasdaq Listing Rule 5635(c)(4). The grants were made to attract the two executives to join the company.

Why it matters — A PETS watcher would care because the equity inducement grants signal the company is adding key new executive hires, which could affect leadership and future direction.

PetMeds Enhances Board of Directors with Appointment of Tamar Elkeles as New Independent Director

GlobeNewsWire · 21 Sept 2026positive

PetMed Express announced the appointment of Dr. Tamar Elkeles as a new independent director on its board of directors. Dr. Elkeles brings deep experience and a proven track record in shaping human capital strategy to support strategic growth and operational execution.

Why it matters — A PETS watcher would care because adding an independent director with expertise in human capital strategy could strengthen the company's leadership and support its strategic growth and operational execution.

PetMeds Appoints Jeff Willard as CEO & President and Announces Board Leadership Transition

GlobeNewsWire · 17 Sept 2026neutral

PetMed Express announced the appointment of Jeff Willard as CEO and President. The company also disclosed a board leadership transition, with Justin Mennen set to succeed Leslie C.G. Campbell as Chair of the Board following her retirement.

Why it matters — A PETS watcher would care because a change in top leadership and board chair can signal shifts in the company's strategic direction and governance.

PetMeds Appoints Andrew Parry as Chief Technology Officer

GlobeNewsWire · 14 Sept 2026neutral

PetMed Express, Inc., the parent company of PetCareRx, announced the appointment of Andrew Parry as Chief Technology Officer, effective immediately. Parry will lead the company's technology strategy, platform architecture, and engineering execution across its e-commerce, pharmacy, and enterprise systems.

Why it matters — The appointment of a dedicated chief technology officer signals a focus on strengthening PetMeds' digital and e-commerce infrastructure, which underpins its core retail operations.

PetMed Express Q1 Earnings Miss Estimates, Sales Decline Y/Y

Zacks Investment Research · 14 Aug 2026negative

PetMed Express reported fiscal first-quarter 2027 results that missed estimates, with sales declining year over year. The company noted signs of progress through lower costs, stronger recurring sales, and new partnerships.

Why it matters — A PETS watcher would care because the earnings miss and year-over-year sales decline are notable even as the company points to cost reductions and growth in recurring sales and partnerships.

FAQ

Frequently asked questions about PETS stock

What is the PETS stock price forecast for 2026-2027?

The 1 Wall Street analysts covering PetMed Express, Inc. have a median 12-month price target of $1.4, with estimates ranging from $1.4 to $1.4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PETS stock a buy right now?

Of the 1 analysts covering PetMed Express, Inc., 0 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks PetMed Express, Inc. 47 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PETS?

As at 12 Oct 2026, PetMed Express, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (86 of 100).

Will PETS stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +11.1% from the last close, and Ticker Nerd's factor model ranks PetMed Express, Inc. 47 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PETS stock forecast for 2030?

No analyst covering PetMed Express, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PETS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.4 to $1.4 over the next 12 months.

How has PETS stock performed over the past year?

PetMed Express, Inc. returned -47.9% over the 12 months to 12 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does PetMed Express, Inc. do?

PetMed Express Inc. is a U.S.-based pet pharmacy and direct-to-consumer retail company that serves pet owners through its 1-800-PetMeds brand.

What is the latest news on PETS?

The most recent item we track (GlobeNewsWire, 2 Oct 2026): "PetMeds Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". PetMed Express, Inc. (PetMeds) announced that it granted equity awards previously approved by its Board of Directors to two newly hired executives as a material inducement to employment, under Nasdaq Listing Rule 5635(c)(4). The grants were made to attract the two executives to join the company.

Company

About PetMed Express, Inc.

PetMed Express Inc. is a U.S.-based pet pharmacy and direct-to-consumer retail company that serves pet owners through its 1-800-PetMeds brand. PetMed Express Inc. markets prescription and non-prescription pet medications, health products, and supplies for dogs, cats, and horses, with offerings that include flea and tick preventives, joint care products, vitamins, supplements, hygiene items, food, treats, and other wellness essentials. The company operates through online and phone-based channels, using its e-commerce platform and licensed pharmacy operations to provide convenient home delivery of pet care products across the United States. Its business is centered on companion-animal health, making it a recognized participant in the pet healthcare and online retail markets.

CEO Ms. Leslie C. G. Campbell · 189 employees · United States · https://www.1800petmeds.com